the second course, and none of the 12 initially non-responders or partial responders improved with the second course of therapy. The mechanisms of this failure are not known, but one explanation could be acquired drug resistance.
We have previously developed two substrains of cultured human epithelial cells which are resistant to otherwise lethal concentrations (2 imol/l) of auranofin, a drug containing gold (I).5 One substrain (HE(,,x)) was orginally made resistant to 100 p.mol/l of cadmium chloride6 and contained high amounts of cytosolic metallothionein (MT), a metal binding protein induced by cadmium pretreatment. The demonstrated binding of gold by MT is one possible mechanism of auranofin resistance in these cells. On sodium aurothiomalate exposure (25-300 smolUl), however, no differences in sensitivity to the growth inhibitory effect were observed between the HEI (,) cells and the parent cell line.7 Another substrain (HEAF) developed resistance to auranofin during exposure to stepwise increased concentrations of the drug in the culture medium. In these cells cytosolic gold was bound by low molecular weight gold binding proteins appearing on auranofin treatment. Furthermore, the HEAF cells had the capacity to depress the cellular gold concentration.
The present study was undertaken to investigate whether the parent line of human epithelial cells could also acquire resistance to the antiproliferative effect of sodium aurothiomalate during exposure to stepwise increasing concentrations of the drug. We also investigated possible mechanisms for the development of resistance, including MT 
